Skip to main content

The independent medical news service

Prostate cancer

19-10-2020 | Oncology | News | Article

Olaparib recommended for BRCA-mutated metastatic CRPC

Click through to read this EMA update

12-10-2020 | Oncology | News | Article

Studies support early salvage radiotherapy after prostatectomy

Data from the phase 3 RADICALS-RT, RAVES, and GETUG-AFU 17 trials and the ARTISTIC meta-analysis suggest that observation with early salvage radiotherapy should be the standard of care for men undergoing radical prostatectomy for localized or locally advanced prostate cancer.

08-10-2020 | Oncology | News | Article

Combining ipatasertib with abiraterone may benefit some mCRPC patients

Dual pathway inhibition with the AKT inhibitor ipatasertib plus the androgen receptor inhibitor abiraterone may benefit certain patients with treatment-naïve, metastatic castration-resistant prostate cancer, phase 3 IPATential150 trial data suggest.

10-09-2020 | Oncology | News | Article

Post-radiotherapy ipilimumab shows long-term survival benefits in mCRPC

Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.

04-09-2020 | Oncology | News | Article

Rucaparib has ‘meaningful’ antitumor activity in BRCA-mutated mCRPC

Phase 2 TRITON2 study data suggest that men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 mutation may benefit from treatment with the PARP inhibitor rucaparib.

19-08-2020 | Oncology | News | Article

Radiotherapy delays may not adversely affect prostate cancer OS

Starting radiotherapy up to 6 months after androgen deprivation therapy may be feasible for men with intermediate- and high-risk localized prostate cancer, say US researchers who found that overall survival was comparable regardless of the timing of radiotherapy initiation.

07-08-2020 | Oncology | News | Article

Neoadjuvant chemohormonal therapy not yet encouraged for localized prostate cancer

The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.

31-07-2020 | Oncology | News | Article

Cancer diagnostic delays due to COVID-19 may lead to high excess mortality

Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.

29-07-2020 | Oncology | News | Article

ADT tied to reduced COVID-19 severity

Receipt of androgen deprivation therapy may be associated with less severe COVID-19 outcomes, suggest data from New York City.

17-07-2020 | Oncology | News | Article

HSD3B1 variant shows minimal added value as treatment biomarker in mCRPC

The HSD3B1 CC pathogenic variant does not add prognostic information to standard clinical variables for men receiving abiraterone or enzalutamide for metastatic castration-resistant prostate cancer, study findings indicate.

03-07-2020 | Oncology | News | Article

Updated ESMO prostate cancer guidelines released

Click through for more information on these Clinical Practice Guidelines

03-07-2020 | Oncology | News | Article

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

24-06-2020 | Oncology | News | Article

Antiandrogen therapy boosts nonmetastatic CRPC survival

Adding an androgen receptor inhibitor to androgen deprivation therapy significantly improves the overall survival of men with nonmetastatic castration-resistant prostate cancer, according to results from three trials.

11-06-2020 | Oncology | News | Article

CONDOR: 18F-DCFPyL PET diagnoses biochemically recurrent prostate cancer

Positron-emission tomography using the novel prostate-specific membrane antigen targeted 18F-DCFPyL tracer shows “excellent diagnostic performance” in men with biochemically recurrent prostate cancer, researchers report.

02-06-2020 | Oncology | News | Article

Relugolix may offer better testosterone suppression than leuprolide

Men with advanced prostate cancer who receive the gonadotropin-releasing hormone antagonist relugolix are more likely to have sustained suppression of testosterone than those treated with leuprolide acetate, HERO trial data show.

29-05-2020 | Oncology | News | Article

FDA approves rucaparib, olaparib for mutated metastatic CRPC

Read more on these decisions

27-05-2020 | Oncology | News | Article

Data question ADT omission when using EBRT plus brachytherapy boost

Adding androgen deprivation therapy to external beam radiotherapy may result in better survival than adding a brachytherapy boost in men with intermediate- and high-risk prostate cancer, network meta-analysis data suggest.

22-05-2020 | Oncology | News | Article

Data reinforce HSD3B1 variant link to poor mCRPC outcome

Men with metastatic castration-resistant prostate cancer (mCRPC) who carry the CC genotype of the HSD3B1 c.1245A>C variant have worse responses to first-line abiraterone and enzalutamide than those with an AA or AC genotype, research shows.

13-05-2020 | Oncology | News | Article

EMA supports hybrid cabazitaxel formulation for mCRPC

Click here to read more

07-05-2020 | Oncology | News | Article

Link between ADT and reduced COVID-19 risk proposed

An analysis of Italian patients suggests a potential protective role of androgen deprivation therapy against SARS-CoV-2 infection.

Image Credits